Asset

SCYLLO-INOSITOL

OPKO Health Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (5)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01791725phase2completed2013-09-012014-06-01OPKO Health, Inc.A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
NCT00934050phase2completed2009-06-012011-06-01OPKO Health, Inc.ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
NCT00568776phase2completed2007-12-012010-05-01OPKO Health, Inc.ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT01735630phase2completed2012-11-012015-05-01OPKO Health, Inc.Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01674010phase2terminated2012-08-012014-06-01OPKO Health, Inc.Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)